Recipient of federal assistance · BLACKSBURG, VA

BIOTHERAPEUTICS, INC.

BIOTHERAPEUTICS, INC. received $1.3M in federal grants and other assistance in FY2026, on 15 actions, −59% vs FY2025. It has no federal contracts in the loaded years. Since FY2021: $10.4M. Its largest awarding agency was National Institutes of Health ($1.3M).

Assistance · FY2026
$1.3M
New awards
3
Actions
15
Since FY2021
$10.4M
UEI
DKZNEQL174E3
Location
BLACKSBURG, VA
Businesses
Open in the explorerFederal grants & assistance

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

Assistance by fiscal year

  1. 2.4MFY2021
  2. 563.7KFY2022
  3. 2MFY2023
  4. 944.9KFY2024
  5. 3.2MFY2025
  6. 1.3MFY2026

By type

  1. Grants$1.3M100%

Top programs · Awarding agencies

Obligations in FY2026.

Top programs

  1. 93.855 · Allergy and Infectious Diseases Research$628.7K48%
  2. 93.866 · Aging Research$500K38%
  3. 93.846 · Arthritis, Musculoskeletal and Skin Diseases Research$191.3K14%

Awarding agencies

  1. National Institutes of Health$1.3M100%
    Department of Health and Human Services

Largest awards

  1. A FIRST-IN-CLASS TOPICAL IMMUNOREGULATORY THERAPEUTIC FOR PSORIASIS - A FIRST-IN-CLASS TOPICAL IMMUNOREGULATORY THERAPEUTIC FOR PSORIASIS…$2M
    93.846 · Arthritis, Musculoskeletal and Skin Diseases Research· National Institutes of Health· Project grant· Sep 22, 2025 – Sep 17, 2026· R44AR083730
  2. NOVEL IMMUNOREGULATORY THERAPEUTICS FOR SYSTEMIC LUPUS ERYTHEMATOSUS - NOVEL IMMUNOREGULATORY DRUGS FOR SYSTEMIC LUPUS ERYTHEMATOSUS…$1.1M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Jun 27, 2022 – Dec 17, 2025· R44AI156952
  3. COMPUTATIONAL MODELING OF IMMUNE RESPONSES TO CLOSTRIDIUM DIFFICILE INFECTION FOR PREDICTING THERAPEUTIC EFFICACY$555.6K
    12.351 · Scientific Research - Combating Weapons of Mass Destruction· Defense Contract Management Agency· Project grant· May 5, 2021 – Jun 17, 2026· HDTRA12010021
  4. IMMUNOMETABOLIC THERAPEUTICS FOR ALZHEIMER'S DISEASE - IMMUNOMETABOLIC THERAPEUTICS FOR ALZHEIMER’S DISEASE BIOTHERAPEUTICS INC (BTI) IS AN…$500K
    93.866 · Aging Research· National Institutes of Health· Project grant· Sep 18, 2026 – Sep 18, 2026· R43AG102078
  5. NEXT-GEN ORAL THERAPEUTICS FOR TYPE 2 DIABETES - NEXT-GEN ORAL THERAPEUTICS FOR TYPE 2 DIABETES BIOTHERAPEUTICS INC (BTI) IS A…$359.6K
    93.847 · Diabetes, Digestive, and Kidney Diseases Extramural Research· National Institutes of Health· Project grant· Jun 20, 2025 – May 4, 2026· R43DK142279
  6. DEVELOPMENT OF NOVEL IMMUNOREGULATORY THERAPEUTICS FOR ASTHMA - DEVELOPMENT OF NOVEL IMMUNOREGULATORY THERAPEUTICS FOR ASTHMA…$355.9K
    93.837 · Cardiovascular Diseases Research· National Institutes of Health· Project grant· Sep 17, 2024 – Jul 13, 2026· R43HL172516

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 8, 2026, loaded Oct 8, 2026 · FY2021–FY2026.